Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53 - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Blood Année : 2019

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Karim Maloum
  • Fonction : Auteur
  • PersonId : 882079
Catherine Settegrana
  • Fonction : Auteur
  • PersonId : 931419
Virginie Eclache
Marc Muller
Nathalie Nadal
  • Fonction : Auteur
Olivier Bernard
  • Fonction : Auteur
  • PersonId : 864298

Résumé

B-cell prolymphocytic leukemia (B-PLL) is a rare hematological disorder whose underlying oncogenic mechanisms are poorly understood. Our cytogenetic and molecular assessment of 34 patients with B-PLL revealed several disease-specific features and potential therapeutic targets. The karyotype was complex ({greater than or equal to}3 abnormalities) in 73% of the patients and highly complex (>5 abnormalities) in 45%. The most frequent chromosomal aberrations were translocations involving MYC [t(MYC)] (62%), deletion (del)17p (38%), trisomy (tri)18 (30%), del13q (29%), tri3 (24%), tri12 (24%), and del8p (23%). Twenty-six of the 34 patients (76%) exhibit MYC aberration, resulting from mutually exclusive translocations or gains. Whole-exome sequencing revealed frequent mutations in TP53, MYD88, BCOR, MYC, SF3B1, SETD2, CHD2, CXCR4, and BCLAF1 The majority of B-PLL used the IGHV3 or IGHV4 subgroups (89%), and displayed significantly mutated IGHV genes (79%). We identified three distinct cytogenetic risk groups: low-risk (no MYC aberration), intermediate-risk (MYC aberration but no del17p), and high-risk (MYC aberration and del17p) (p=.0006). In vitro drug response profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodomain and extra-terminal motif (BET) inhibitor targeting MYC) was associated with significantly lower viability of B-PLL cells harboring a t(MYC). We conclude that cytogenetic analysis is a useful diagnostic and prognostic tool in B-PLL. Targeting MYC may be a useful treatment option in this disease.
Fichier principal
Vignette du fichier
Chapiro et al. 2019 text.pdf (880.2 Ko) Télécharger le fichier
Chapiro et al. 2019 Figures.pdf (410.09 Ko) Télécharger le fichier
Supplementary Information Chapiro et al. 2019.pdf (2.33 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02363995 , version 1 (14-11-2019)

Identifiants

Citer

Elise Chapiro, Elodie Pramil, M'Boyba Diop, Damien Roos-Weil, Clémentine Dillard, et al.. Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood, 2019, 134 (21), pp.1821-1831. ⟨10.1182/blood.2019001187⟩. ⟨hal-02363995⟩
117 Consultations
119 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More